Everyone Is Watching Ozempic. Nobody Is Watching the Pen That Decides Who Gets Them.

The most wanted medicine in the world was never the scarce thing. The device it ships inside was. And the same bottleneck decides who gets the next vaccine.

For two years the most sought-after drugs on earth were rationed, and almost everyone misread what was being rationed. The story was told as a shortage of a miracle: not enough Ozempic, not enough Wegovy, not enough of the molecule that quiets appetite and is rewriting the economics of obesity. Pharmacies ran dry. Patients hunted across state lines. A gray market of copies bloomed to fill the gap. And through all of it the thing that was actually scarce was not the drug.

It was the pen. The small, single-use injector that delivers the dose, and the specialized factory lines that fill those pens one sterile unit at a time, were the bottleneck the whole time. The companies had the medicine. What they could not do, fast enough, was put it into the device that lets you take it. The shortage everyone watched was a shortage of plastic and precision, not of chemistry, and the proof is in what the manufacturers did to escape it.

This is not only a story about diet drugs. The same step that rationed Ozempic is the step that rationed the COVID vaccines, and is the step that would ration the next one. Fill-finish is the narrow end of nearly every injectable a country can deploy in a hurry, which makes it the narrow end of pandemic response, of insulin, of the biologics a health system leans on when something goes wrong at scale. The weight-loss shortage was a live, public stress test of that capacity, run on the most-demanded drug in the world, and the system failed it for two years.

The molecule was never the floor

A finished injectable drug is two separate problems wearing one label. There is the active ingredient, the molecule, made in bulk by chemical synthesis. And there is what the industry calls fill-finish: taking that bulk drug and filling it, under sterile conditions, into the exact device a patient will use, the prefilled pen, then assembling, inspecting, and packaging it. The molecule is one factory. The pen is another, and a far more constrained one.

Aseptic fill-finish is among the hardest, slowest steps in all of pharmaceutical manufacturing. Every unit is filled in a sterile environment to a precision that cannot fail, because a contaminated injectable kills. The injector pen itself is a small precision machine, multiple molded and metal parts assembled to fire a fixed dose reliably in a shaking hand. The lines that do this work are few, expensive, and slow to build.

So a drug can be abundant at the molecule and scarce at the pen at the same time, and to the patient at the counter the two are indistinguishable. The shelf is empty either way. A drug you can synthesize but cannot fill into its device is not a supply. It is an inventory you cannot ship.

The proof is the vial

If this were merely a story about a popular drug catching up to demand, the manufacturers would have poured their money into making more molecule. They did the opposite, and what they did is the proof.

Eli Lilly, facing the same wall, did something revealing: it began shipping its drug in plain single-dose vials, no pen at all, a syringe-and-vial format that sidesteps the injector entirely. That move is a confession in plastic. You only remove the pen if the pen is the problem. Lilly ran the counterfactual in public, and it worked, because the constraint was never the chemistry.

Novo, for its part, spent to own the bottleneck. Novo Holdings acquired the contract manufacturer Catalent for roughly 16.5 billion dollars, and Novo Nordisk took three of its fill-finish plants for around 11 billion. You do not spend sixteen and a half billion dollars buying a fill-finish company because you are short of an ingredient. You spend it because the ingredient is fine and the bottleneck is downstream, at the pen. The constraint is named most clearly not by analysts but by where the capital runs, and the capital ran to fill-finish.

The few factories that fill the world’s pens

Bulk drug synthesis is spread across many plants and many countries; the chemistry is mature and licensable. Sterile fill-finish and device assembly are not. They are concentrated in a small set of specialized contract manufacturers, the CDMOs, and in a handful of device makers whose names almost no patient knows, firms like Ypsomed and Phillips-Medisize that design and assemble the injectors the brands put their labels on. The drug company on the box is often not the company that fills the pen.

When demand for an injectable explodes, every brand competes for time on the same scarce fill-finish lines. The drugmaker can flood its own synthesis as fast as it likes and still wait in a queue for the step that puts the drug into the device. The bottleneck is not the molecule and not even the pen. It is the small number of places on earth that can fill the pen to standard, and there is no app for building another one fast.

The qualification wall

A fill-finish line is not a thing you switch on. It is a thing you qualify, and qualification is the wall that makes the chokepoint durable. A new sterile-filling line must be built, then validated, then qualified against regulatory standards that exist because a contaminated injectable is lethal, and only then can it ship a single commercial unit. The process runs for years, not months.

This is why money is a weak and slow lever here. You can buy a fill-finish company in an afternoon, as Novo did, and still wait years for the pens to flow, because the binding constraint was never capital. It was qualified sterile capacity, and that has a clock money cannot reset. The cheque clears in a day. The line clears in years.

The molecule is almost never the limit

This is not a quirk of one drug class. It is the general shape of how modern medicine reaches a body. The EpiPen shortages that left allergic patients hunting for their rescue device were never a shortage of epinephrine, a cheap and ancient drug off patent for generations; they were a shortage of the autoinjector, a device dependent on a single dominant assembler whose line problems became a national shortage of a life-saving product whose drug was never short. The COVID vaccines told the same story from the other direction: once the formula was proven, the global bottleneck was fill-finish, the vials and the filling lines, and nations competed for slots on the world’s limited sterile-filling capacity while the recipe sat ready.

The reason is structural. Synthesis is chemistry, and chemistry industrializes; sterile device-filling is a precision craft with few qualified lines and long build times. And the trend runs one way: medicine is shifting steadily from pills toward injectable biologics, the drugs that must be filled into devices, which means the fill-finish chokepoint does not shrink with progress. It grows with it. The last mile of medicine is a chokepoint by construction, and it is the chokepoint that decides, again and again, who gets treated.

The size of the want against the size of the line

To feel the bottleneck you have to hold two numbers in the same hand. The want is enormous: obesity affects a large share of adults across the wealthy world, which makes the addressable population not the millions of a typical blockbuster but the hundreds of millions, a market analysts call potentially the largest in pharmaceutical history. The line is small: a finite number of qualified fill-finish suites, each filling pens at a fixed rate, shared across every injectable a manufacturer sells.

Lay the want against the line and the shortage stops being a surprise and becomes arithmetic. When demand is counted in hundreds of millions and the constraint in a handful of sterile suites, no price closes the gap quickly. A want that scales in a year cannot be met by a line that scales in five, and the distance between those two speeds is the shortage. What chemistry makes abundant, the pen makes scarce; and what the pen makes scarce, no chemistry can release.

What the bottleneck rationed

A constraint this tight does not just slow supply. It allocates. While the pens were short, demand poured into a parallel market of compounded copies, mixed by pharmacies under a regulatory exception that applies during official shortages. An entire telehealth industry grew inside the gap the pen had opened, prescribing compounded semaglutide and tirzepatide under two regulatory categories, the 503A compounders and the larger 503B facilities, both permitted to copy a drug only while it sits on the official shortage list.

Then the bottleneck eased, and the easing rewrote the rules again. The FDA declared the shortages resolved, tirzepatide in December 2024 and semaglutide in February 2025, and the compounding exception closed behind it, with enforcement ending in early 2025 and court fights as compounders resisted the cutoff. The same constraint that created the gray market then erased it, on the manufacturers’ timeline. And the gray market carried a cost: by spring 2025 the FDA had logged more than 500 adverse-event reports tied to compounded semaglutide and over 400 tied to compounded tirzepatide, with at least seventeen deaths associated with compounded versions. The harms were not a side effect of the drug. They were a side effect of the constraint. The pen did not only decide how much drug existed. It decided who was allowed to make it, and when they had to stop.

Who the pen left waiting

Translate the bottleneck into people and it stops being a supply-chain abstraction. For two years, getting one of these medicines was a lottery run by fill-finish capacity. Patients rationed their own doses, skipped weeks, switched molecules when their pen vanished, or paid out of pocket for a compounded copy of uncertain quality. Diabetics who had used the same injectable for years found it diverted to weight-loss demand the same pen lines could not also serve. The shortage fell hardest on whoever had the least ability to chase supply, which is the usual signature of a rationed good.

None of this was visible as a device story. It was experienced as luck, as a pharmacy saying yes or no, as a price. But the luck had a cause, and the cause was upstream, in how many pens the world could fill that month. The shortage was lived as a personal misfortune and produced as an industrial constraint.

The pen is also a moat

There is a second face to the device. The injector pen is not only a constraint the makers fought to widen. It is also an asset they have reason to keep. A proprietary pen ties the patient to the brand, makes switching harder, and turns a molecule that will one day go generic into a device-and-drug system that is harder to copy. The same object that bottlenecked supply also fortifies the franchise.

This does not mean the shortage was manufactured. But the device sits where a genuine production limit and a genuine commercial advantage coincide. And the Catalent deal sharpened the point: Catalent was a neutral contract filler that served many companies. When it passed to a buyer tied to a single competitor in the hottest drug market on earth, a piece of the industry’s shared capacity moved from a neutral party into one of the players who depend on it. A bottleneck is a fact of physics until someone buys it, and then it is a position.

The geography of who gets filled

The chokepoint also has a map, and the map decides who gets treated worldwide. Sterile fill-finish capacity is concentrated in a handful of wealthy countries, the same United States and Europe where Novo and Lilly placed the plants they bought and built. When a device-limited drug is rationed, it is rationed outward from where the pens are filled, which means the rich markets are served first and the rest of the world waits, not because the molecule is unavailable but because the filling lines are somewhere else. A medicine with global demand reaches people in the order their countries sit from the fill-finish plant. The discovery belongs to humanity. The pen belongs to a postal code.

The next wave is already being decided by the device

The companies are racing to develop oral versions, GLP-1 medicines in a pill rather than an injection, and the loudest reason given is patient preference. The deeper reason is the pen. A pill needs no aseptic fill-finish, no autoinjector, no sterile device line. It bypasses the entire chokepoint. Whichever company delivers an effective oral version escapes the constraint that rationed the injectables for two years, and that escape, not any difference in the molecule, may decide who wins the largest drug market in history. When the bottleneck is the last mile, the prize goes to whoever finds a route that skips it.

The same law in a different industry

The binding constraint on a powerful new thing is almost never the idea. It is the capacity to make the idea at scale, hidden in an unglamorous step downstream of the breakthrough. In the Second World War the Allies did not lack aircraft designs; they were rationed by machine tools and trained labor. In the chip war the contest is not over who can design a processor but over the few plants and the single Dutch lithography machine that can print one. In ammunition, the wall is not the shell but the explosive fill and the few lines that load it. The molecule, the blueprint, the design: these scale and copy. The last physical step, the one that needs a qualified line and years to build, does not, and so it decides.

The pens are this law in pharmaceutical form. A society that measures progress by discovery will keep being surprised by shortages, because it watches the half of the system that makes headlines and ignores the half that makes the product. Invention is what gets announced. Production is what gets rationed.

The strongest case against reading it this way

The honest objection is that this is just the normal ramp of a blockbuster, and that calling the pen the constraint is a distinction without a difference. A brand-new drug with explosive demand will always be short at first; the pen and the molecule are both just parts of making a drug.

The objection fails on the one fact it cannot absorb: the vial. If the pen and the molecule were interchangeable parts of one undifferentiated problem, you could not relieve the shortage by removing the pen. But Lilly relieved it precisely by removing the pen and shipping in a vial, and Novo spent billions buying the capacity to fill more pens, not to make more molecule. When the people with the most information and money all move on the same variable, that variable was the constraint. The ramp was real. The thing it was waiting on was the pen. Where a future drug is genuinely limited by the inability to make the molecule, the pen is not the story and this reading does not apply; the claim is specific to the case where synthesis is solved and the device is not, which is exactly what the vial and the sixteen billion dollars show.

What the boom was really limited by

The weight-loss drugs will keep being narrated as a story about a molecule, measured in waistlines and stock prices. Watch the device under the drug. The pace at which this revolution reached people was set, and for the next wave of injectables will again be set, not by the brilliance of the chemistry but by the throughput of sterile fill-finish and the supply of a small plastic injector most patients never give a second look.

Everyone watched the drug. The thing that decided whether the drug in the headline became the drug in your hand was a pen, and the few quiet factories that fill it. The shortage was never a shortage of the cure. It was a shortage of the last three seconds between the cure and the patient, and those three seconds were owned by a device.

**The Manifest Archive publishes the complete version, with full analysis on themanifestarchive.com. Free to read**